SNS Financial Group’s Charles River Laboratories CRL Stock Holding History

SNS Financial Group’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$215K	Buy	+949	New	+$169K	﹤0.01%	517

Other funds holding CRL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

VBA

Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return

SNS Financial Group's CRL Position: Q2 2026 in Review

SNS Financial Group opened a new position in Charles River Laboratories (CRL) in Q2 2026: 949 shares worth $215K. The stake represents ﹤0.01% of the portfolio and ranks #517 among its holdings.

348 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

SNS Financial Group held 949 shares of Charles River Laboratories worth $215K as of Q2 2026.
Charles River Laboratories was a new SNS Financial Group position in Q2 2026.
Charles River Laboratories made up ﹤0.01% of SNS Financial Group's portfolio in Q2 2026, its #517 holding.
348 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on SNS Financial Group's 13F filing for Q2 2026, filed 11 Aug 2026.